9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Items 501–600 of 1,000
Di, X., Xiang, L., Jian, Z., Xia, Z., & Luo, D. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.139436 · Cited by 14
Nomoto, H., Takahashi, Y., Takano, Y., Yokoyama, H., Tsuchida, K., Nagai, S., Miya, A., Kameda, H., Cho, K. Y., Nakamura, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082163 · Cited by 15
The protective role of GLP-1 in neuro-ophthalmology
Sheth, S., Patel, A., Foreman, M. A., Mumtaz, M., Reddy, A., Sharaf, R., Sheth, S., & Lucke-Wold, B. P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00015 · Cited by 15
Chen, S., Lu, J., Peng, D., Liu, F., Lu, W., Zhu, W., Bao, Y., Zhou, J., & Jia, W. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110987 · Cited by 13
Neuroprotective effects of oral metformin before stroke on cerebral small-vessel disease
Akiyama, N., Yamashiro, T., Ninomiya, I., Uemura, M., Hattori, Y., Ihara, M., Onodera, O., & Kanazawa, M. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.122812 · Cited by 12
Clinical research using real-world data: A narrative review
Kimura, Y., Jo, T., Matsui, H., & Yasunaga, H. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.08.002 · Cited by 12
Feng, Q., Wu, M., & Mai, Z. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1482918 · Cited by 13
“Dapagli fl ozin became the fi rst SGLT-2i to receive approval, launching in Europe in 2012 and subsequently being approved by the Food and Drug Administration in 2013 for the treatment of T2DM (12).”
SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
Block, C. E. M. D. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30031-7 · Cited by 14
Add-on value of tirzepatide versus semaglutide
Scheen, A. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00116-4 · Cited by 14
Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis
Scarton, L. J., Jo, A., Xie, Z., O’Neal, L. J., Pena, J. M. M., George, T. J., & Bian, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275681 · Cited by 11
Bielinski, S. J., Cardozo, L. L. Y., Takahashi, P. Y., Larson, N. B., Castillo, A., Podwika, A., Filippis, E. D., Hernandez, V., Mahajan, G., Gonzalez, C., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac759 · Cited by 14
Laursen, H. V. B., Jørgensen, E. P., Vestergaard, P., & Ehlers, L. H. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01268-5 · Cited by 14
Utzschneider, K. M., Younes, N., Butera, N. M., Balasubramanyam, A., Bergenstal, R. M., Barzilay, J. I., Desouza, C. V., DeFronzo, R. A., Elasy, T. A., Krakoff, J. A., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1059 · Cited by 12
Silpa, N., Vaishalini, V., Lakshmi, S. V. S. S., Rao, V. V. R. M., Kurada, R. R., & Bonthu, S. (2023) · International Conference on Integrated Intelligence and Communication Systems (ICIICS) · doi:10.1109/iciics59993.2023.10421410 · Cited by 12
“The set of researchers [1, 2, 3, 4, 5, 6, 7, 8, 9] explored various health issues, including treatment standards, gestational diabetes prediction, heart disease assessment, and biosensors for precise diabetes predictions.”
BackgroundDar, M. A., Siddiqui, N. A., Mir, S. R., Akbar, S., Mothana, R. A., & Masoodi, M. H. (2024) · Open Chemistry · doi:10.1515/chem-2024-0025 · Cited by 15
Yandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 15
Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Ena, J., Gómez‐Huelgas, R., & Carretero‐Gómez, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.06.005 · Cited by 13
John, M., Kalra, S., & Nair, T. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.07.009 · Cited by 13
Ciardullo, S., Trevisan, R., & Perseghin, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105530 · Cited by 13
Manu, P., Rogozea, L. M., & Cernea, S. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001401 · Cited by 13
Kuchay, M. S., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102446 · Cited by 13
Pérez, M. B., Hsia, D. S., Sloan, L. A., Nell, H., Mungur, O., Hovsepian, L., Schmider, W., Spranger, R., Yang, N., & Niemoeller, E. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13343 · Cited by 14
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Hropot, T., Battelino, T., & Dovč, K. (2022) · Hormone Research in Paediatrics · doi:10.1159/000527653 · Cited by 12
“…Standards of Medical Care in Diabetes by the American Diabetes Association recommend using SGLT2 inhibitors with or without metformin as initial therapy for individuals with type 2 diabetes at higher risk for heart failure, chronic kidney disease, and/or atherosclerotic cardiovascular disease [20].”
Tajima, A., Tobe, K., Eiki, J., Origasa, H., Watada, H., Shimomura, I., Tokita, S., & Kadowaki, T. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003032 · Cited by 15
Švehlíková, E., Ashcroft, N. L., Gatschelhofer, C., GERRING, D. J., Höller, V., Jezek, J., Lackner, B., Lawrence, F., Pillai, V., Ratzer, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1054 · Cited by 12
Abushanab, D., Liew, D., Marquina, C., Al‐Badriyeh, D., & Ademi, Z. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.07.018 · Cited by 12
Viljoen, A., Pantalone, K. M., Galindo, R. J., Cui, X., Huh, R., Hemmingway, A., Fernández Landó, L., & Patel, H. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01398-1 · Cited by 11
Verma, S., Sabbour, H. M., Alamuddin, N., Alawadi, F., Alkandari, H., Almahmeed, W. A., Assaad-Khalil, S. H., HADDAD, J. A., Lombard, L., Malik, R. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15011 · Cited by 11
“…as per the current American Diabetes Association 32 and European Association for the Study of Diabetes guidelines recommending GLP-1 RAs and SGLT2is to individuals with T2D and ASCVD as well as patients with T2D and ASCVD risk (or indicators of risk), 33 and the American College of Cardiology.”
Zhang, J., Xu, H., Lu, J., Dong, Y., & Feng, J. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117291 · Cited by 11
Insight into the role of PCSK9 in glucose metabolism
Xu, J., Wang, T., Shu, H., Shi, S., Tao, L., & Li, J. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117444 · Cited by 11
Lucero, K. S., Larkin, A. T., Zakharkin, S. O., Wysham, C., & Anderson, J. E. (2023) · JMIR Medical Education · doi:10.2196/48586 · Cited by 11
Elsherif, I., Jammah, A. A., Ibrahim, A. R., Alawadi, F., Sadek, I. S., Rahman, A. M., Sharify, G. E., AlFeky, A., Aldossari, K. K., Roushdy, E., et al. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.06.003 · Cited by 11
López, M. A. B., Camafort, M., Ruíz, R. C., Cuenca, A. M. C., Gargallo-Fernández, M., de Paz, H. D., Redondo‐Antón, J., Artime, E., Díaz‐Cerezo, S., & Santos, M. R. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02938-2 · Cited by 11
Feng, L., Jinhua, W., Shulin, G., Jiangping, X., Zhongxiang, L., & Xiaohong, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1414958 · Cited by 11
Cotton, A. H., Salerno, P. R. V. D. O., Deo, S. V., Virani, S. S., Nasir, K., Neeland, I. J., Rajagopalan, S., Sattar, N. A., Al-Kindi, S. G., & Elgudin, Y. E. (2024) · Scientific Reports · doi:10.1038/s41598-024-73974-9 · Cited by 13
“Given these cardiovascular benefits, based on recommendations from the American Diabetes Association, either or both agents would now be considered first-line drugs for a large proportion of CKM patients 4 .”
BackgroundLiu, D., Du, Y., Yao, X., Wei, Y., Zhu, J., Cui, C., Zhou, H., Xu, M., Li, H., & Ji, L. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101185 · Cited by 11
Franchi, M., Pellegrini, G., Avogaro, A., Buzzetti, G., Candido, R., Cavaliere, A., Consoli, A., Marzona, I., Mennini, F. S., Palcic, S., et al. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003991 · Cited by 11
Ferrannini, E., Niemoeller, E., DEX, T. A., Servera, S., & Mari, A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14688 · Cited by 12
Individualized Glycemic Goals for Older Adults Are a Moving Target
Pilla, S. J., Yazdi, Z. S., & Taylor, S. I. (2022) · Diabetes Care · doi:10.2337/dci22-0004 · Cited by 11
White, A., Bradley, D. P., Buschur, E., Harris, C., LaFleur, J., Pennell, M. L., Soliman, A., Wyne, K. L., & Dungan, K. M. (2022) · JMIR Diabetes · doi:10.2196/33401 · Cited by 12
Al‐Salameh, A., Bouzegaoui, N. E., & Saraval, M. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.09.023 · Cited by 14
Haluzík, M., Seufert, J., Guja, C., Bonnemaire, M., Bigot, G., Tournay, M., Kis, J. T., & Freemantle, N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01375-8 · Cited by 11
Liu, G., Zhong, X., Zheng, J., Zhang, J., Kong, W., Hu, X. F., Min, J., Xia, W., Zeng, T., & Chen, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01391-8 · Cited by 13
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 12
Guarnotta, V., Emanuele, F., Salzillo, R., Bonsangue, M., Amato, C., Mineo, M. I., & Giordano, C. S. D. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1248985 · Cited by 11
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Dagli, N., Kumar, S., Ahmad, R., Narwaria, M., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.46510 · Cited by 16
Omachi, T., Ohara, M., Fujikawa, T., Kohata, Y., Sugita, H., Irie, S., Terasaki, M., Mori, Y., Fukui, T., & Yamagishi, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01493-3 · Cited by 11
“Based on the positive results of these clinical trials, the American Diabetes Association and European Association for the Study of Diabetes Consensus Report recommend the use of GLP-1RAs for treating patients with T2DM with atherosclerotic CVD and/or multiple coronary risk factors [8].”
Marigliano, M., Piona, C. A., Mancioppi, V., Morotti, E., Morandi, A., & Maffeis, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15432 · Cited by 13
Yang, Y., Kim, N. H., Baek, J. H., Ko, S., Son, J. W., Lee, S., Rhee, S. Y., Kim, S., Sohn, T. S., Jun, J. E., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0225 · Cited by 13
Wong, C. K. H., Man, K. K. C., Shi, M., Chan, E. W., Ho, C. W., Tse, E. T. Y., Wong, I. C. K., & Lam, C. L. K. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002999 · Cited by 11
Recent therapeutic targets in diabetic nephropathy
Mohsen, M., Elberry, A. A., Rabea, A. M., Abdelrahim, M. E. A., & Hussein, R. R. S. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14650 · Cited by 12
Eghbali‐Zarch, M., Tavakkoli-Moghaddam, R. R., Esfahanian, F., & Masoud, S. (2022) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-022-02602-3 · Cited by 11
Synergism between metformin and analgesics/vitamin B12 in a model of painful diabetic neuropathy
Pecikoza, U. B., Tomic´, M. A., Nastić, K., Micov, A. M., & Stepanović-Petrović, R. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113441 · Cited by 11
Novitasari, D., Fitriana, A. S., Yantoro, A. T., & Enarga, A. B. P. (2022) · KOLABORASI JURNAL PENGABDIAN MASYARAKAT · doi:10.56359/kolaborasi.v2i5.175 · Cited by 11
Zhang, Y., Wang, J., Jiang, L., Wang, T., Li, Z., Fu, X., Huang, W., Xiao, Y., Wang, S., & Zhao, J. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00929-3 · Cited by 11
Nomoto, H., Takahashi, A., Nakamura, A., Kurihara, H., Takeuchi, J., Nagai, S., Taneda, S., Miya, A., Kameda, H., Cho, K. Y., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002988 · Cited by 11
Jensen, J., Poulsen, M. K., Petersen, P. W., Gerdes, B., Rossing, K., & Schou, M. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14324 · Cited by 12
Zekry, R., Omran, G. A., El-Gharbawy, N. M., & Werida, R. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-33417-3 · Cited by 11
Hong, S., Han, K., & Park, C. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.06.010 · Cited by 11
Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection
Cho, E.-H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0372 · Cited by 11
Di Molfetta, S., Bosi, E., Ceriello, A., Cucinotta, D., Tiengo, A., Scavini, M., Piccolo, C., Bonizzoni, E., Acmet, E., & Giorgino, F. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109070 · Cited by 10
Nemlekar, P. M., Hannah, K. L., & Norman, G. J. (2023) · Clinical Diabetes · doi:10.2337/cd22-0080 · Cited by 10
Fuentes, S., Hrzic, R., Haneef, R., Kab, S., Cosson, E., & Fosse‐Edorh, S. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100137 · Cited by 11
SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective
KUMAR, K. M. P., Unnikrishnan, A., Jariwala, P. V., Mehta, A., Chaturvedi, R., Panchal, S., Lakhani, P., Acharya, R., & Dixit, J. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_377_23 · Cited by 11
“[24,25] When SGLT2i are used in hyperglycaemic conditions, ~40%−50% of unabsorbed glucose is available for reabsorption at the later part of proximal tubules; this indirectly increases the transport maximum of the SGLT1 receptor capacity in the distal tubules.”
BackgroundThe effect and mechanism of liraglutide on the biological functions of BMSCs in diabetic patients
Wang, Y., Sun, Y., Yang, B., Li, J., & Liang, C. (2024) · Oral Diseases · doi:10.1111/odi.14931 · Cited by 11
Hong, G., Zhou, Y., Yang, S., Yan, S., Lu, J., Xu, B., Zhan, Z., Jiang, H.-S., Wei, B., & Wang, J. (2024) · Stem Cells · doi:10.1093/stmcls/sxae057 · Cited by 10
Sinclair, M. R., Ardehali, M. M., Diamantidis, C. J., & Corsino, L. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1412874 · Cited by 10
Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
Vigara, L. A., Villanego, F., Orellana, C., Eady, M., Sánchez, M. G., Alonso, M., García, M. B., Amaro, J. M., García, T. G., & Mazuecos, A. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.007 · Cited by 13
Gul, U., Aung, T., Martin, M., Farrukh, D. N., Shah, P., Lovely, Z. S., León, E. M., Alansaari, M., Maini, S., Fariduddin, M. M., et al. (2024) · Cureus · doi:10.7759/cureus.76519 · Cited by 16
Bergstein, V. E., Ekkel, K., Haft, M. A., Mikula, J. D., Best, M. J., & Srikumaran, U. (2025) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2024.11.041 · Cited by 11
Hou, W. C., Tuttle, K. R., Shen, W., Reikes, A., & Watanabe, J. H. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70108 · Cited by 11
Wang, J., Lee, C., Ko, W., Wu, L., & Chang, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112324 · Cited by 11
Al‐Saleh, Y., Busaidi, N. A., Dahi, W. A. A., Almajnoni, M., Mohammed, A. S., Alshali, K. Z., Alshamiri, M. Q., Sifri, S. A., Arafah, M., Chan, S. P., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02529-7 · Cited by 12
“In patients with a compelling need to minimise hypoglycaemia, preferred agents include DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors and/or thiazolidinediones [21].”
BackgroundHagi, K., Kochi, K., Watada, H., Kaku, K., & Ueki, K. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14035 · Cited by 13
Contemporary Medical Management of Peripheral Arterial Disease
Cook, I. O., & Chung, J. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07516-2 · Cited by 16
“The American Diabetic Association guidelines recommend considering the use of SGLT2 inhibitors in patients with type 2 DM and elevated ASCVD risk, kidney disease, or heart failure, particularly before initiating insulin [50].”
Zhang, P., Shen, Y., Xu, X. H., Ding, B., Yan, R., Wang, H.-Y., Xie, X., Ma, J., & Hu, Y. Y. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i7.1489 · Cited by 11
Allamreddy, S. R., Arora, M., Ganugula, R., Friend, R., Basu, R., & Kumar, M. N. V. R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001074 · Cited by 12
Siriyotha, S., Anothaisintawee, T., Looareesuwan, P., Nimitphong, H., McKay, G. J., Attia, J., & Thakkinstian, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086424 · Cited by 13
“10 Furthermore, GLP-1 RAs have been approved for the treatment of obesity regardless of the presence of DM. 11 While the advantages of GLP-1 RAs in reducing weight have been well established in highly screened RCTs, their effectiveness in real-world settings across a heterogeneous population is…”
Chen, B., Tao, L., Tian, M., & Ji, Z. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.01.056 · Cited by 11
Gao, M. H., Giamouridis, D., Lai, N. C., Guo, T., Xia, B., Kim, Y. C., Huu, V. A. N., Skowronska‐Krawczyk, D., Lantier, L., Bhargava, R., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.002 · Cited by 11
Wei, E. T., Koh, E., Kelly, M. S., Wright, L. A.-C., & Tylee, T. S. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.02.030 · Cited by 10
Kobayashi, K., Toyoda, M., Hatori, N., Sakai, H., Furuki, T., Sato, K., Terauchi, Y., Tamura, K., & Kanamori, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-20313-5 · Cited by 12
Yu, Y., Yang, X., Tong, K., Yin, S., Hu, G., Zhang, F., Jiang, P., Zhou, M., & Jian, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1041044 · Cited by 11
Singh, H., Singh, J., Bhangu, R. K., Singla, M., Singh, J., & Javid, F. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2163386 · Cited by 10
Luo, Y., Chang, Y., Zhao, Z., Xia, J., Xu, C., Bee, Y. M., Li, X., Sheu, W. H., McGill, M. J., Chan, S. P., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100746 · Cited by 15
Jin, J., Cui, G., Mi, N., Wu, W., Zhang, X., Xiao, C., Wang, J., Qiu, X., Han, M., Li, Z., et al. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106448 · Cited by 10
Qie, S., Li, X., Wang, X., Liu, Y., Li, J., & Liu, G. (2020) · Endocrine · doi:10.1007/s12020-020-02193-9 · Cited by 12
Buniam, J., Chansela, P., Weerachayaphorn, J., & Saengsirisuwan, V. (2023) · Biomedicines · doi:10.3390/biomedicines11072071 · Cited by 9
Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St. Peter, W. L. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.09.016 · Cited by 9
Patient adherence in healthcare operations: A narrative review
Kılıç, H., & Güneş, E. D. (2023) · Socio-Economic Planning Sciences · doi:10.1016/j.seps.2023.101795 · Cited by 12
Chen, I., Pai, Y., Lin, J., Chen, Y., Lin, K., Chen, H., & Lin, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112167 · Cited by 10
Semaglutide and diabetic retinopathy: an OHDSI network study
Cai, C. X., Nishimura, A., Baxter, S. L., Goetz, K., Hribar, M. R., Toy, B. C., Barkmeier, A. J., Wang, S. Y., Swaminathan, S. S., Flowers, A. M., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005424 · Cited by 12
The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes
Ruda, A. I., Ciobanu, D. M., Inceu, G., Rusu, A., & Román, G. (2022) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2425 · Cited by 9
Anderson, J. E., Gavin, J. R., Kruger, D. F., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0020 · Cited by 10
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
Heller, S. R., Raposo, J. F., Tofé, S., Hanif, W., Schroner, Z., Down, S., & Blevins, T. (2022) · Clinical Diabetes · doi:10.2337/cd22-0016 · Cited by 9
Reyes‐García, R., Moreno, Ó., Bellido, V., Botana-López, M. A., Rodríguez-Hervada, A. D., Fernández‐García, D., Fernández‐García, J. C., Gargallo-Fernández, M., González-Clemente, J. M., Jódar-Gimeno, E., et al. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.07.006 · Cited by 14
Siriyotha, S., Lukkunaprasit, T., Looareesuwan, P., Nimitphong, H., McKay, G. J., Attia, J. R., & Thakkinstian, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01641-2 · Cited by 10
Principles of Pharmacogenomics and Pharmacogenetics
Hasanzad, M., Sarhangi, N., Hashemian, L., & Sarrami, B. (2022) · Springer eBooks · doi:10.1007/978-981-19-5082-7_2 · Cited by 9
Scheen, A. J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-54 · Cited by 9
Kang, X., Sun, Y., Duan, Y., Zhang, Y., Xuedong, A., Jin, D., Lian, F., & Tong, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1142327 · Cited by 9
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.